why choose us

Clinical Trials Search

Showing 8,340 of 132,656 result(s)
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate;Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

Status: Completed

Condition: Asthma

Interventions: Fluticasone Propionate;Salbutamol Sulfate.
Oral inhalation powder.

Date: 2023-09-18

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

Status: Completed

Condition: Non-alcoholic Steatohepatitis

Interventions: Subcutaneous injection administered at a dose of 7 mg

Date: 2023-09-18

DBS for Depression

Status: Completed

Condition: Treatment Resistant Depression

Interventions: At the ninth month post DBS implantation, the participant will enter a discontinuation phase of a duration of 6 weeks.
The device will be turned

Date: 2023-09-18

Open Label - Personalized Therapeutic Neuromodulation for Anhedonic Depression

Status: NOT_YET_RECRUITING

Condition: Treatment Resistant Depression

Interventions:

Participants will receive intermittent TBS to left DLPFC.
The L-DLPFC will be targeted utilizing the Localite neuronavigation system.
Sti

Date: 2023-09-18

The Effects of Playful Pathways

Status: Completed

Condition: Gross Motor Development Delay

Interventions: Group session for gross motor development

Date: 2023-09-17

Hand-Foot Exercises on Peripheral Neuropathy

Status: COMPLETED

Condition: Breast Cancer

Interventions:

The exercise group will participate in home-based hand and foot exercises for 8 weeks.
The exercise program will start the week the first neur

Date: 2023-09-17

Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

Status: NOT_YET_RECRUITING

Condition: Chronic Low-back Pain

Interventions: Subjects enrolled in the trial will receive CELZ-201-DDT at the specified dose into the lumbar paraspinal musculature.
Each subject will receive

Date: 2023-09-17

Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

Status: ACTIVE_NOT_RECRUITING

Condition: COVID-19

Interventions:

Drug product RQ-001 is the fully assembled device consisting of the vial containing RQ-01 and the actuator.
Drug Product RQ-001 has been devel

Date: 2023-09-17

A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)

Status: COMPLETED

Condition: Idiopathic Pulmonary Fibrosis

Interventions: REGEND001: 1-1.5×10^6 bronchial basal cells;kg administrated by bronchoscopy.

Date: 2023-09-17

YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis

Status: COMPLETED

Condition: Atherosclerotic Cardiovascular Disease

Interventions: In single ascending dose (SAD) part of study in health subjects, YN001 will be administrated one time with dosage from 10 mg to 120 mg (planned).

Date: 2023-09-16